Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Arvinas's ARV-766?
ARV-766 is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
ARV-766 by Novartis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
ARV-766 is under clinical development by Novartis and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Risk adjusted net present value: What is the current valuation of Arvinas's ARV-766?
ARV-766 is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....